New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: VIVUS, Inc (NASDAQ:VVUS), XOMA Corp (NASDAQ:XOMA), Newcastle Investment Corp (NYSE:NCT), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
VIVUS, Inc (NASDAQ:VVUS) showed a volume of 2.69 million shares by the end of last trade whereas the average volume of the stock remained 1.97 million shares. The stock opened the session at $8.36 but then moved to $7.93. At that price, the stock showed a negative performance of -2.94%. VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese),
Will VVUS Get Buyers Even After The Recent Rally? Find Out Here
XOMA Corp (NASDAQ:XOMA) opened the session at $7.43 and closed the session at $7.39. The stock showed a negative performance of -1.60% in previous trading session. Traded with volume of 2.63 million shares in the prior session and the average volume of the stock remained 2.45 million shares. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta).
Has XOMA Found The Bottom And Ready To Gain Momentum? Find Out Here
Newcastle Investment Corp (NYSE:NCT) opened the session at $5.72 and closed the session at $5.61. The stock showed a negative performance of -1.58% in previous trading session. Traded with volume of 3.34 million shares in the prior session and the average volume of the stock remained 3.64 million shares. The beta of the stock remained 3.23. Newcastle Investment Corp. (Newcastle) is a real estate investment and finance company. Newcastle invests in, and actively manages, a portfolio of, real estate securities, loans, excess mortgage servicing rights (MSRs) and other real estate related assets.
Why Should Investors Buy NCT After the Recent Fall? Just Go Here and Find Out
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) the stock decreased -8.70% and finished the session at $5.55. Traded with volume of 2.60 million shares in the prior session and the average volume of the stock remained 2.04 million shares. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Will MACK Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)